(IN BRIEF) Aviva and mixed-use developer Socius have been selected as the preferred bidders for the advancement of the London Cancer Hub (LCH), a world-leading district dedicated to cancer research and treatment in Sutton, London. The partnership will collaborate with … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Insurance, Investment, Management, News, United Kingdom
Tagged Aviva, Barry Jessup, bidders, Charlotte Jones, Cllr Ruth Dombey OBE, Dame Cally Palmer, Epsom & St Helier University Hospitals NHS Trust, Gillian Norton, Institute for Cancer Research, London Borough of Sutton, London Cancer Hub Development, partnership, Professor Paul Workman, Royal Marsden NHS Foundation Trust, Socius, sustainability
LONDON, 16-Nov-2017 — /EuropaWire/ — The Institute of Cancer Research, London, welcomes the approval by NICE of a new type of treatment for women with previously untreated advanced breast cancer. Palbociclib and ribociclib, two new drugs approved today for use on the NHS, … Read the full press release
Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs. BRIGHTON, 2-3-2015 — /EuropaWire/ — A major computational analysis by scientists at the University of Sussex and The Institute of Cancer Research, … Read the full press release
Posted in Education, Healthcare, Science, United Kingdom
Tagged Cancer Research UK, Daphne Jackson Trust, Dr Bissan Al-Lazikani, Dr Frances Pearl, drugs that exploit the inherent weaknesses of cancer cells, Nature Reviews Cancer, Professor Laurence Pearl, Professor Paul Workman, The Institute of Cancer Research, The Institute of Cancer Research scientists, Tony Carr, University of Sussex
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
